NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
GSR Commits $100M to Hare Onchain Credit Vaults 
Tabletop particle accelerator could transform medicine and materials science 
Wall Street Rises as Oil Prices Ease, Nasdaq Hits Record 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Asian Currencies Mixed as Yen Weakens, Dollar Holds Firm 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
Gold Prices Fall as Stronger Dollar Weighs on Bullion 
Iran Tanker Attacks Surge as Hormuz Oil Flows Near Prewar Levels 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Add as a preferred source on Google
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
